Systematic review: Reliability of compendia methods for off-label oncology indications

Annals of Internal Medicine

Volumn 150, Issue 5, 2009, Pages 336-343

  Abernethy, Amy P ^a   Raman, Gowri ^b   Balk, Ethan M ^b   Hammond, Julia M ^c   Orlando, Lori A ^c   Wheeler, Jane L ^a   Lau, Joseph ^b   McCrory, Douglas C ^d  

^a DUKE CANCER INSTITUTE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CISPLATIN; DOCETAXEL; ERLOTINIB; GEMCITABINE; IRINOTECAN; OXALIPLATIN; RITUXIMAB; PRESCRIPTION DRUG;

BILIARY TRACT CANCER; BLADDER CANCER; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER THERAPY; CHRONIC LYMPHATIC LEUKEMIA; DRUG APPROVAL; DRUG INDICATION; ESOPHAGUS CANCER; FOOD AND DRUG ADMINISTRATION; HEAD AND NECK CANCER; HUMAN; LUNG CANCER; MONOTHERAPY; OFF LABEL DRUG USE; ONCOLOGY; OVARY CANCER; PANCREAS CANCER; PRESCRIPTION; PRIORITY JOURNAL; RELIABILITY; REVIEW; SCIENTIFIC LITERATURE; STOMACH CANCER; SYSTEMATIC REVIEW; TREATMENT INDICATION; BOOK; COMPARATIVE STUDY; DRUG LABELING; EVIDENCE BASED MEDICINE; LEGISLATION AND JURISPRUDENCE; MEDICAID; MEDICAL LITERATURE; MEDICARE; STANDARDS; UNITED STATES;

ANTINEOPLASTIC AGENTS; DRUG APPROVAL; DRUG LABELING; EVIDENCE-BASED MEDICINE; MEDICAID; MEDICARE; PHARMACOPOEIAS AS TOPIC; PRESCRIPTION DRUGS; REFERENCE BOOKS, MEDICAL; UNITED STATES;

EID: 61449201963     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-150-5-200903030-00107     Document Type: Review

References (16)

1. Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med. 2006;166:1021-6. [PMID: 16682577]
2. ASCO supports government report: "Off-label drugs: reimbursement policies constrain physicians in choice of cancer therapies". Oncology (Williston Park). 1991;5:29-30, 33. [PMID: 1838269]
3. Soares M. "Off-Label" indications for oncology drug use and drug compendia: history and current status. J Oncol Practice. 2005;1:102-5.
4. Social Security Administration. Compilation of the Social Security Laws. Part E - Miscellaneous Provisions: Definitions of Services, Institutions, etc. 42 U.S.C. §1395x, Sec 1861. Accessed at www.ssa.gov/OP-Home/ssact/ title18/1861.htm on 22 January 2009.
5. American Society of Health-System Pharmacists. American Hospital Formulary Service Drug Information. Bethesda, MD: American Society of Health-System Pharmacists; 2006. Updated 2008.
6. Klasco R. United States Pharmacopeia Drug Information for the Health Professional. New York: Thomson Reuters; 2006.
7. American Society of Clinical Oncology. Reimbursement for cancer treatment: coverage of off-label drug indicadons. J Clin Oncol. 2006;24:3206-8. [PMID: 16717290]
8. Compendia 1861(t)(2)-And-cancer. Baldmore, MD: Centers for Medicare and Medicaid Services; 2008. Accessed at www.cms.hhs.gov/CoverageGenInfo/02- compendia.asp on 20 August 2008.
9. Wasco R, ed. DRUGDEX System. New York: Thomson Reuters; 2006. Updated 2008.
10. Facts and Comparisons. Drug Facts and Comparisons 2006. St. Louis: Wolters Kluwer Health; 2006. Updated 2008.
11. National Comprehensive Cancer Network. National Comprehensive Cancer Network Drugs and Biologies Compendium 2006. Jenkintown, PA: National Comprehensive Cancer Network; 2006. Updated 2008.
12. Gold Standard. Clinical Pharmacology. Tampa, FL: Gold Standard Multimedia; 2006. Updated 2008.
13. Abernethy AP, Hammond JM, Hubbard ML, Patwardhan MB, Orlando LA, McCrory DC, et al; Agency for Healthcare Research and Quality. Compendia for coverage of off-label uses of drugs and biologies in an anti-cancer chemotherapeutic regimen. Rockville, MD: Agency for Healthcare Research and Quality; 2007. Accessed at www.cms.hhs.gov/determinadonprocess/downloads/id46TA. pdf on 20 August 2008.
14. von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al. Gemcitabine and cisplatin versus methotrexate, vinblasdne, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18:3068-77. [PMID: 11001674]
15. von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cispladn, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23:4602-8. [PMID: 16034041]
16. Roberts JT, von der Maase H, Sengelov L, Conte PF, Dogliotti L, Oliver T, et al. Long-term survival results of a randomized trial comparing gemcitabine/cispladn and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer. Ann Oncol. 2006; 17 Suppl 5:v118-22. [PMID: 16807438]